Objective: During the coronavirus disease-2019 (COVID19) pandemic, antibiotics were widely used in many countries without regard for the general rules of antibiotic use. This intense antibiotic use is thought to have caused antimicrobial resistance in agents that cause ventilator-associated pneumonia (VAP). This study aimed to compare antimicrobial resistance patterns of VAP agents before and during the COVID-19 pandemic. Material and Methods: This retrospective cohort study involved patients diagnosed with VAP before and during COVID19 in a training and research hospital. The antimicrobial resistance patterns of VAP agents were examined in endotracheal aspirate samples. Results: The results were compared between the COVID-19 and pre-COVID-19 groups. From 178 patients who met the VAP diagnostic criteria in the intensive care unit, the COVID-19 group comprised 107, and the preCOVID-19 group, 71. In both periods, Acinetobacter baumannii was the most common infectious agent, followed by Pseudomonas aeruginosa (35.2%) in the pre-COVID-19 period. During the COVID-19 pandemic, Klebsiella pneumoniae was the second most common infectious agent (20.6%). During the COVID-19 pandemic, there was an increase in antimicrobial resistance to piperacillin-tazobactam, ciprofloxacin, amikacin, and cefepime antibiotics compared to before. Conclusion: The results of this study demonstrated increased antimicrobial resistance in some microorganisms that caused VAP in COVID-19 patients receiving mechanical ventilator support in the intensive care unit. The increased resistance pattern may have contributed to the failure to treat VAP. Determination of the antibiotic resistance patterns is essential concerning reducing treatment failures and preventing antimicrobial resistance.
Keywords: Acinetobacter baumannii; antimicrobial resistance; critical care; ventilator-associated pneumonia
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] salgını sırasında antibiyotikler, antibiyotik kullanımının genel kurallarına bakılmaksızın birçok ülkede yaygın olarak kullanıldı. Bu yoğun antibiyotik kullanımının, ventilatör ilişkili pnömoniye (VİP) neden olan etkenlerde antimikrobiyal dirence neden olduğu düşünülmektedir. Bu çalışma, COVID-19 salgını öncesi ve sırasında VİP etkenlerinin antimikrobiyal direnç paternlerini karşılaştırmayı amaçlamaktadır. Gereç ve Yöntemler: Bu retrospektif kohort çalışmasına, bir eğitim ve araştırma hastanesinde COVID-19 öncesi ve sırasında VİP tanısı konulan hastalar dâhil edildi. VİP etkenlerinin antimikrobiyal direnç modelleri, endotrakeal aspirat örneklerinde incelendi. Bulgular: Sonuçlar COVID-19 ve COVID19 öncesi gruplar arasında karşılaştırıldı. Yoğun bakım ünitesinde VİP tanı kriterlerini karşılayan 178 hastadan 107'si COVID-19 grubunda, 71'i ise COVID-19 öncesi grubunda yer aldı. Her iki dönemde de en sık görülen enfeksiyon etkeni Acinetobacter baumannii iken COVID-19 öncesi dönemde bunu Pseudomonas aeruginosa (%35,2) izledi. COVID-19 pandemisi sırasında ise Klebsiella pneumoniae ikinci en sık görülen enfeksiyon etkeniydi (%20,6). COVID-19 pandemisi sırasında, pandemi öncesi döneme göre piperasilin-tazobaktam, siprofloksasin, amikasin ve sefepim antibiyotiklerine karşı antimikrobiyal dirençte artış görüldü. Sonuç: Bu çalışmanın sonuçları, yoğun bakımda mekanik ventilatör desteği alan COVID-19 hastalarında VİP etkeni olan bazı mikroorganizmalarda antimikrobiyal direncin arttığını göstermiştir. Artan direnç paterni, VİP tedavisindeki başarısızlığa katkıda bulunmuş olabilir. Antibiyotik direnç paternlerinin belirlenmesi, tedavi başarısızlıklarının azaltılması ve antimikrobiyal direncin önlenmesi açısından önemlidir.
Anahtar Kelimeler: Acinetobacter baumannii; antimikrobiyal direnç; yoğun bakım; ventilatör-ilişkili pnömoni
- Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-10. [Crossref] [PubMed] [PMC]
- Ghanizadeh A, Najafizade M, Rashki S, Marzhoseyni Z, Motallebi M. Genetic diversity, antimicrobial resistance pattern, and biofilm formation in Klebsiella pneumoniae isolated from patients with coronavirus disease 2019 (COVID-19) and ventilator-associated pneumonia. Biomed Res Int. 2021;2021:2347872. [Crossref] [PubMed] [PMC]
- Kariyawasam RM, Julien DA, Jelinski DC, Larose SL, Rennert-May E, Conly JM, et al. Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021). Antimicrob Resist Infect Control. 2022;11(1):45. [Crossref] [PubMed] [PMC]
- Segala FV, Bavaro DF, Di Gennaro F, Salvati F, Marotta C, Saracino A, et al. Impact of SARS-CoV-2 epidemic on antimicrobial resistance: a literature review. Viruses. 2021;13(11):2110. [Crossref] [PubMed] [PMC]
- Jamnani AN, Montazeri M, Mirzakhani M, Moosazadeh M, Haghighi M. Evaluation of bacterial coinfection and antibiotic resistance in patients with COVID-19 under mechanical ventilation. SN Compr Clin Med. 2022;4(1):19. [Crossref] [PubMed] [PMC]
- Spalding MC, Cripps MW, Minshall CT. Ventilator-associated pneumonia: new definitions. Crit Care Clin. 2017;33(2):277-92. [Crossref] [PubMed] [PMC]
- Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. Erratum in: Clin Infect Dis. 2017;64(9):1298. Erratum in: Clin Infect Dis. 2017;65(8):1435. Erratum in: Clin Infect Dis. 2017;65(12):2161. [PubMed] [PMC]
- Sarı S, Arslan F, Turan S, Mengi T, Ankaralı H, Sarı A, et al. Comparison of the healthcare-associated infections in intensive care units in Turkey before and during COVID-19. Egypt J Intern Med. 2023;35(1):30. [Crossref] [PubMed] [PMC]
- Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020;20(1):646. [Crossref] [PubMed] [PMC]
- Bahçe YG, Acer Ö, Özüdoğru O. Evaluation of bacterial agents isolated from endotracheal aspirate cultures of Covid-19 general intensive care patients and their antibiotic resistance profiles compared to pre-pandemic conditions. Microb Pathog. 2022;164:105409. [Crossref] [PubMed] [PMC]
- Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al; coVAPid study Group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47(2):188-98. Erratum in: Intensive Care Med. 2022;48(4):514-5. [PubMed] [PMC]
- Fumagalli J, Panigada M, Klompas M, Berra L. Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients. Curr Opin Crit Care. 2022;28(1):74-82. [Crossref] [PubMed] [PMC]
- Giacobbe DR, Battaglini D, Enrile EM, Dentone C, Vena A, Robba C, et al. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. J Clin Med. 2021;10(4):555. [Crossref] [PubMed] [PMC]
- Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS One. 2020;15(8):e0237831. [Crossref] [PubMed] [PMC]
- Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. [Crossref] [PubMed] [PMC]
- Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of hypertension on the severity of COVID-19: a review. J Cardiovasc Pharmacol. 2021;78(5):e648-e55. [Crossref] [PubMed] [PMC]
- Porto APM, Borges IC, Buss L, Machado A, Bassetti BR, Cocentino B, et al; HAI/COVID-19 Brazilian Task Force. Healthcare-associated infections on the intensive care unit in 21 Brazilian hospitals during the early months of the coronavirus disease 2019 (COVID-19) pandemic: an ecological study. Infect Control Hosp Epidemiol. 2023;44(2):284-90. [Crossref] [PubMed] [PMC]
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55. Erratum in: Lancet. 2022;400(10358):1102. [PubMed] [PMC]
- Arshad AR, Ijaz F, Siddiqui MS, Khalid S, Fatima A, Aftab RK. COVID-19 pandemic and antimicrobial resistance in developing countries. Discoveries (Craiova). 2021;9(2):e127. [Crossref] [PubMed] [PMC]
.: Process List